Cellectis SA
ALCLS
Company Profile
Business description
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.
Contact
8, rue de la Croix Jarry
Paris75013
FRAT: +33 181691600
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
229
Stocks News & Analysis
stocks
Chart of the Week: Has gold reached bear market territory?
Investors are facing a shifting landscape.
stocks
Fair value upgrade for this ASX income player
Headwinds in listed energy stocks likely to have passed
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,885.60 | 59.90 | 0.68% |
| CAC 40 | 7,971.11 | 154.17 | 1.97% |
| DAX 40 | 23,273.72 | 593.68 | 2.62% |
| Dow JONES (US) | 46,341.51 | 1,125.37 | 2.49% |
| FTSE 100 | 10,368.43 | 191.98 | 1.89% |
| HKSE | 25,260.76 | 472.62 | 1.91% |
| NASDAQ | 21,590.63 | 795.99 | 3.83% |
| Nikkei 225 | 53,739.68 | 2,675.96 | 5.24% |
| NZX 50 Index | 12,825.87 | 86.24 | -0.67% |
| S&P 500 | 6,528.52 | 184.80 | 2.91% |
| S&P/ASX 200 | 8,671.80 | 53.10 | 0.62% |
| SSE Composite Index | 3,948.55 | 56.69 | 1.46% |